Darbepoetin Alfa

Darbepoetin alfa is a synthetic, long-acting erythropoiesis-stimulating agent (ESA). It is a 165-amino acid protein produced via recombinant DNA technology in Chinese hamster ovary cells. **Clinical Pearl**: Compared to epoetin alfa (rHuEPO), darbepoetin contains two additional N-linked carbohydrate chains. This structural modification increases its molecular weight and dramatically increases its metabolic stability and half-life, allowing for less frequent dosing (e.g., once weekly instead of three times weekly). It is primarily used off-label in veterinary medicine to manage non-regenerative anemia associated with chronic kidney disease (CKD) in dogs and cats. Theoretically, the extra carbohydrate shielding may make it less immunogenic than epoetin alfa, potentially reducing the risk of pure red cell aplasia (PRCA), though this remains unproven in veterinary patients.

กลไกการออกฤทธิ์: Darbepoetin alfa mimics endogenous erythropoietin by binding to the **erythropoietin receptor (EpoR)** on the surface of erythroid progenitor stem cells in the bone marrow. * Binding induces receptor dimerization → activates the **JAK2/STAT5** intracellular signaling pathway. * This cascade → inhibits apoptosis of progenitor cells → stimulates their proliferation and differentiation into mature **red blood cells (RBCs)**. * The increased RBC mass subsequently raises the packed cell volume (PCV) and improves tissue oxygenation.

ข้อมูลอ้างอิงยาของ VetSheet มีไว้สำหรับสัตวแพทย์ผู้มีใบอนุญาตเพื่อช่วยในการตัดสินใจทางคลินิก ไม่ใช่สิ่งทดแทนการวินิจฉัยของผู้เชี่ยวชาญหรือฉลากล่าสุดของผู้ผลิต